Financial Performance - Revenue for the year ended December 31, 2024, was RMB 156,367,000, a decrease of 23.3% compared to RMB 203,964,000 in 2023[14] - Gross profit for 2024 was RMB 86,676,000, down from RMB 125,133,000 in 2023, reflecting a gross margin decline[14] - Loss before tax increased to RMB 268,701,000 in 2024, compared to RMB 145,859,000 in 2023, indicating a worsening financial position[14] - The company reported a loss per share of RMB 2.50 for 2024, compared to RMB 1.28 in 2023, indicating increased losses on a per-share basis[14] - Net assets decreased to RMB 1,276,602,000 in 2024 from RMB 1,557,784,000 in 2023, a reduction of 18.0%[14] - Revenue decreased by 23.3% from RMB204.0 million for the year ended December 31, 2023 to RMB156.4 million for the year ended December 31, 2024, primarily due to the impact of myopia prevention and control product policies[160] - Cost of sales decreased by 11.6% from RMB78.8 million for the year ended December 31, 2023 to RMB69.7 million for the year ended December 31, 2024, attributed to reduced revenue and improved efficiency[163] - Gross profit decreased from RMB125.1 million for the year ended December 31, 2023 to RMB86.7 million for the year ended December 31, 2024, with gross profit margin declining from 61.4% to 55.4%[164] - Other income and gains decreased from RMB58.1 million for the year ended December 31, 2023 to RMB32.2 million for the year ended December 31, 2024, mainly due to reduced interest income[168] - R&D expenses decreased by 8.9% from RMB111.6 million for the year ended December 31, 2023 to RMB101.7 million for the year ended December 31, 2024, due to strengthened project management and reduced labor costs[169] - Selling and distribution expenses decreased by 25.3% from RMB100.6 million for the year ended December 31, 2023 to RMB75.2 million for the year ended December 31, 2024, primarily due to centralized management and personnel optimization[175] - Administrative expenses increased by 12.7% from RMB99.0 million for the year ended December 31, 2023 to RMB111.6 million for the year ended December 31, 2024, primarily due to increased employee termination payments[176] - The company recorded a loss of RMB265.1 million for the year ended December 31, 2024, compared to a loss of RMB145.7 million for the year ended December 31, 2023, representing an increase in loss of 82.1%[184] - The increase in loss was primarily due to a loss allowance of RMB23.7 million related to regulatory changes affecting laser-based myopia treatment devices, an increase of RMB22.3 million in share-based payments, and an impairment of goodwill of RMB43.2 million[184] Asset Management - Total current assets decreased to RMB 894,222,000 in 2024 from RMB 1,281,927,000 in 2023, a decline of 30.2%[14] - Non-current assets increased significantly to RMB 517,244,000 in 2024, up from RMB 402,985,000 in 2023, showing investment in long-term assets[14] - Current liabilities increased to RMB 122,391,000 in 2024 from RMB 110,237,000 in 2023, reflecting a rise in short-term financial obligations[14] - The company's property, plant, and equipment decreased to RMB16.5 million as of December 31, 2024, from RMB18.0 million as of December 31, 2023, primarily due to depreciation and cleanup of damaged equipment[186] - Inventories decreased to RMB31.2 million as of December 31, 2024, from RMB40.1 million as of December 31, 2023, due to sales-oriented production and improved inventory management[191] - Trade receivables decreased to RMB46.5 million as of December 31, 2024, from RMB79.6 million as of December 31, 2023, attributed to a decrease in gross trade receivables and an increase in impairment loss[192] - The company recognized a loss allowance of RMB39.2 million for trade receivables during the reporting period, with RMB23.7 million related to sales contracts of laser-based myopia treatment devices[193] Product Development and Innovation - The company plans to strengthen its technological foundation and optimize operational efficiency to address market challenges[16] - In 2024, the company maintained the competitiveness of its existing algorithm platforms while making significant progress in the research and development of Large Language Models and successfully filed a national deep synthesis service algorithm[17] - The company launched two landmark portable fundus cameras, the AI-FUNDUSCAMERA-M series and the new generation P-series, enhancing clinical applications and expanding its product matrix[20] - The non-invasive light-based myopia treatment device utilizing PBM-LED technology received medical device certification from the NMPA, becoming the first product of its kind in China to achieve this certification[22] - The company is strategically expanding from a B-end service solution provider to also offering C-end health solutions with the new P-series portable fundus camera scheduled for launch in 2025[21] - The integrated intelligent medical product matrix includes systems for fundus disease detection, myopia prevention, and visual function training, consolidating the company's leading position in intelligent medical treatment[19] - The company has developed a comprehensive product matrix that includes three major AI-enabled medical product lines: Retinal Detection AI, Myopia Prevention and Control AI, and Visual Training AI[51] - The dual-engine strategy of precise detection and innovative treatment enhances market operation synergy and expands product reach to various healthcare settings[44] - Airdoc's AI-empowered retinal image recognition technology addresses significant unmet medical needs for early detection and diagnosis of chronic diseases[52] - The visual training AI product series incorporates AI-powered eye-tracking and training modules, achieving innovative breakthroughs in clinical applications[53] - The company has adjusted its product pipeline to focus on integrated diagnosis and treatment products in response to market demand[63] - The myopia treatment device has been integrated with a self-developed large language model, enhancing its capabilities as a "home optometrist" for personalized intervention[140] - The company continues to invest in R&D for the WanYu LLM technology, integrating it into products and services for enhanced medical solutions[155] Market Expansion and Strategy - Airdoc aims to expand application scenarios to solidify the groundwork for long-term development amidst industry policy adjustments[16] - The company plans to optimize its organization and improve efficiency in 2025, aiming to significantly narrow losses and increase the revenue share of treatment services[31] - National policies have stabilized, with LED-based myopia control products officially categorized as Class II medical devices, which is expected to boost revenues for the company's products[30] - The company aims to enhance its global footprint by expanding into markets such as Malaysia, Singapore, Thailand, the UAE, and South Africa, with a focus on the Middle East in 2025[152] - The company plans to expand sales channels for AI-assisted diagnostics and invest in treatment businesses, including myopia prevention and visual training, to consolidate long-term strategy[151] Regulatory and Compliance - Regulatory changes from the NMPA impacted the company's laser-based AI myopia prevention products, leading to a decrease in revenue and an impairment of goodwill related to the acquisition of Beijing Zhitong Technology Co., Ltd.[28] - The NMPA issued a notice in June 2023 that stipulates laser myopia treatment devices without Class III medical device certification will not be permitted for production and sales in the PRC effective July 1, 2024[199] Customer Engagement and Service Growth - The company achieved significant growth in the number of primary healthcare sites in 2024, broadening service coverage and enhancing customer access to professional services[27] - The number of active service sites increased from 5,671 to 7,883, representing a year-over-year growth of 39.01%[45] - During the reporting period, Airdoc detected 7.10 million cases, reflecting a year-over-year increase of 3.87%[45] - In 2024, there was a more than 50% year-over-year increase in the number of unique visitors (UVs) in hospitals and primary healthcare within the Airdoc Medical segment[46] - The number of active hospital service sites covered reached 417, representing a year-over-year increase of 51.1%, with detections conducted reaching 401 thousand, up by 65.5% year-over-year[120] - The number of active primary healthcare institution service sites reached 2,092, representing a year-over-year increase of 71.3%, with detections conducted reaching 1,034 thousand, up by 62.6% year-over-year[120] - The company has implemented AI-based solutions in over 350 health checkup centers across China, with some achieving a repurchase rate of over 50% for SaMD products[120] Research and Development Achievements - The company has published over 20 papers in prestigious peer-reviewed journals, validating its AI-empowered early detection and diagnostic solutions[83] - The company has published over 20 papers in influential AI academic conferences, enhancing its credibility in the field[85] - Airdoc-AIFUNDUS has been trained on data from 15 different organizations in China, covering a significant portion of the national population, ensuring effective product applicability across diverse demographics[88] - Airdoc's AI technology has been validated through clinical trials, supporting its early detection and diagnostic solutions for chronic diseases[85] - Research collaboration with Fudan University resulted in a publication demonstrating a novel postoperative refractive power prediction method with greater accuracy than existing methods[92] Patent and Intellectual Property - During the reporting period, Airdoc was granted 40 new patents, bringing the total to 270 patents, including 128 inventions[100] - The company has developed SaMD products for glaucoma and cataracts detection, which received Class II medical device certification in June 2020 and January 2022 respectively[67] - The health risk assessment solution currently supports the identification of 55 types of lesions and disease risks, catering to diverse healthcare needs[70]

Group 1 - The core idea of the news is the integration of AI technology in grassroots healthcare services in Wuyishan City, enhancing chronic disease prevention and management for the elderly and high-risk populations [1][3][5] - Wuyishan City has launched a free health check-up program for individuals aged 65 and above, incorporating new tests for glycosylated hemoglobin and AI retinal screening, creating a closed-loop system for chronic disease management [3][5] - As of early April, 2,228 diabetes patients have undergone screenings for diabetic retinopathy and glaucoma, with 296 high-risk cases identified, allowing timely medical intervention [3] Group 2 - The local health bureau has implemented a three-year action plan for integrated chronic disease management, focusing on expanding and enhancing services for diabetes patients through AI retinal examinations [5][7] - The Airdoc-AIFUNDUS 2.0 software has received certification from the National Medical Products Administration (NMPA), enhancing diagnostic capabilities for various eye diseases in primary healthcare settings [7] - The integration of AI technology is expected to make grassroots healthcare services more intelligent and precise, contributing to the "Healthy China" initiative and improving access to quality medical resources [7]

Financial Performance - For the year ended December 31, 2024, the company reported revenue of RMB 156.37 million, a decrease of 23.3% compared to RMB 203.96 million in 2023[4]. - The company experienced a pre-tax loss of RMB 268.70 million, compared to a pre-tax loss of RMB 145.86 million in the previous year, indicating a significant increase in losses[4]. - The company reported a net loss of RMB 265,073 thousand for 2024, compared to a net loss of RMB 145,654 thousand in 2023, representing an increase in losses of 82%[111]. - The company's total equity decreased to RMB 1,276,602 thousand in 2024 from RMB 1,557,784 thousand in 2023, a decline of 18%[113]. - The company's basic and diluted loss per share was RMB 2.50, compared to RMB 1.28 in the previous year, indicating a worsening financial position[4]. Revenue Breakdown - Revenue from AI retinal detection products was RMB 112,703,000 in 2024, down from RMB 160,465,000 in 2023, representing a decline of 29.8%[127]. - Revenue from the sale of Airdoc-AIFUNDUS (1.0) retinal cameras amounted to RMB 51.9 million[38]. - Revenue from the big health scenario reached RMB 27.6 million during the reporting period[42]. - Revenue from the eye health business was RMB 33.2 million, with overseas revenue reaching RMB 9.6 million, accounting for 6.1% of total revenue[45]. - Revenue from the myopia prevention AI product line reached RMB 28.2 million[47]. Product Development and Innovation - The company has developed a comprehensive product matrix integrating diagnostic and therapeutic functions, including three major medical AI product lines: retinal detection AI, myopia prevention AI, and visual training AI[11]. - The company achieved regulatory approval for Airdoc-AIFUNDUS (1.0) in multiple regions, including the EU, Singapore, and several Southeast Asian countries, enhancing its market presence[5]. - The company launched a portable fundus camera aimed at the family and small business market, which received regulatory certification in January 2025[5]. - The company obtained 40 new patents in 2024, bringing its total patent count to 270, including 128 invention patents[9]. - The company plans to submit applications for new functions and additional product registrations in 2025, including retinal detachment and glaucoma detection[14][16]. Research and Development - The company has a robust R&D strategy, with products at various stages, including early and late development, pilot production, and commercialization[16]. - The company plans to expand its artificial intelligence products and services, allocating HKD 252.1 million (34.85%) for research and development in health risk assessment solutions[103]. - Research and development expenses decreased to RMB 101,693 thousand in 2024 from RMB 111,642 thousand in 2023, a reduction of 8.8%[110]. - The company is focused on research and development (R&D) in the field of software as a medical device (SaMD)[157]. Market Expansion and Strategy - The company plans to expand sales channels and focus on AI-assisted diagnosis and myopia prevention by 2025[52]. - The company is preparing to enter overseas markets, with ongoing expansions in Malaysia, Singapore, Thailand, UAE, and South Africa[52]. - The expected timeline for the next milestones includes multiple product registrations and approvals throughout 2025, indicating a proactive approach to market expansion[16]. Operational Metrics - The number of active service points increased to 7,883, representing a year-on-year growth of 39.01%[10]. - The company served a total of 7.10 million cases through SaMD and health risk assessment solutions, marking a year-on-year increase of 3.87%[10]. - The number of active hospital coverage points for Airdoc-AIFUNDUS (1.0) reached 417, a year-on-year increase of 51.1%, with testing frequency reaching 401,000, up 65.5%[38]. - The number of active coverage points in primary healthcare institutions reached 2,092, a year-on-year increase of 71.3%, with testing frequency reaching 1,034,000, up 62.6%[38]. Financial Position and Assets - Cash and cash equivalents decreased from RMB 891.5 million as of December 31, 2023, to RMB 683.2 million as of December 31, 2024, mainly due to increased cash outflows from operating and investing activities[78]. - The company's current liabilities as of December 31, 2024, were RMB 122.4 million, primarily consisting of accounts payable of RMB 14.0 million and other payables and accrued expenses of RMB 65.0 million[80]. - The company's net current assets decreased from RMB 1,171.7 million as of December 31, 2023, to RMB 771.8 million as of December 31, 2024[83]. - The total salary cost incurred by the company for the year ended December 31, 2024, was RMB 209.7 million, compared to RMB 214.1 million in 2023[97]. Corporate Governance - The audit committee, consisting of three independent non-executive directors, reviewed the annual performance and recommended approval to the board[108]. - Ernst & Young confirmed that the figures in the preliminary announcement align with the group's consolidated financial statements for the year ending December 31, 2024[109]. - The board of directors includes executive directors Zhang Dali, Wang Lin, and Chao, as well as independent non-executive directors Wu Yangfeng, Huang Yanlin, and Wu Haoran[156].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2251） 董事會會議日期 北京鷹瞳科技發展股份有限公司 北京鷹瞳科技發展股份有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈， 董事會將於2025年3月27日（星期四）舉行董事會會議，藉以考慮及批准（其中包括） 本公司及其附屬公司截至2024年12月31日止年度之年度業績及其發佈，並考慮建議 派付末期股息（如有）。 承董事會命 Beijing Airdoc Technology Co., Ltd. 董事會主席 張大磊先生 香港，2025年3月17日 於本公告日期，董事會包括執行董事張大磊先生、王林女士、和超博士及秦勇先 生；及獨立非執行董事武陽豐博士、黃彥林博士及吳浩然先生。 北京鷹瞳科技發展股份有限公司 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部 分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Beijing Airdoc Technology Co., Ltd. 北京鷹瞳科技發展股份有限公司 股東及潛在投資者務請參閱本公司有關本集團於截至2024年12月31日止年度的業績 公告，該公告預期將根據上市規則於2025年3月發佈。 （股份代號：2251） 盈利警告 本公告乃由北京鷹瞳科技發展股份有限公司（「本公司」，連同其附屬公司，「本集 團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09(2)條及香港 法例第571章證券及期貨條例第XIVA部的內幕消息條文作出。 本公司董事（「董事」）會（「董事會」）謹此通知本公司股東（「股東」）及潛在投資者，根 據董事會對本集團截至2024年12月31日止年度的未經審核綜合管理賬目草擬稿的初 步評估及董事會現時可得的其他資料，本集團預期於截至2024年12月31日止年度錄 得未經審核虧損介乎人民幣250百萬元至人民幣270百萬元（2023年 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何 部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Beijing Airdoc Technology Co., Ltd. 北京鷹瞳科技發展股份有限公司 （股份代號：2251） 更換聯席公司秘書及 豁免嚴格遵守上市規則第3.28條及第8.17條 更換聯席公司秘書 北京鷹瞳科技發展股份有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事 （「董事」）會（「董事會」）謹此公佈楊文婷女士（「楊女士」）已辭任本公司聯席公司秘書 （「聯席公司秘書」）一職，自2025年1月20日起生效，以便專注於本公司首席財務官 一職。 楊女士確認彼與董事會並無任何意見分歧，亦無有關其辭任之事宜需提請本公司股 東及香港聯合交易所有限公司（「聯交所」）垂注。 董事會亦公佈王新鳳女士（「王女士」）已獲委任為聯席公司秘書，自2025年1月20日 起生效。現任聯席公司秘書蘇麗珊女士（「蘇女士」）將繼續擔任本公司現有職務。 王女士及蘇女士的履歷詳情載列如下： 王女士 王女士於2021年3 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 北京鷹瞳科技發展股份有限公司(「本公司」) (於中華人民共和國註冊成立的股份有限责任公司) 呈交日期： 2025年1月8日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02251 | 說明 H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（ ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 北京鷹瞳科技發展股份有限公司(「本公司」) (於中華人民共和國註冊成立的股份有限责任公司) 呈交日期： 2025年1月7日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02251 | 說明 | H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 北京鷹瞳科技發展股份有限公司(「本公司」) (於中華人民共和國註冊成立的股份有限责任公司) 呈交日期： 2025年1月6日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02251 | 說明 | H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 北京鷹瞳科技發展股份有限公司(「本公司」) (於中華人民共和國註冊成立的股份有限责任公司) 確認 呈交日期： 2025年1月3日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02251 | 說明 | H股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 ...